Transcriptomics

Dataset Information

2

The HDAC inhibitor panobinostat (LBH589) inhibits Acute Lymphoblastic leukemia (ALL) in vitro and in vivo in a new characterized human ALL mice model


ABSTRACT: This SuperSeries is composed of the following subset Series: GSE26789: The HDAC inhibitor panobinostat (LBH589) inhibits Acute Lymphoblastic leukemia (ALL) in vitro and in vivo in a new characterized human ALL mice model (ALL-B and ALL-T) GSE26790: The HDAC inhibitor panobinostat (LBH589) inhibits Acute Lymphoblastic leukemia (ALL) in vitro and in vivo in a new characterized human ALL mice model (TOM-1 and MOLT-4) GSE26791: The HDAC inhibitor panobinostat (LBH589) inhibits Acute Lymphoblastic leukemia (ALL) in vitro and in vivo in a new characterized human ALL mice model (Illumina) GSE26792: The HDAC inhibitor panobinostat (LBH589) inhibits Acute Lymphoblastic leukemia (ALL) in vitro and in vivo in a new characterized human ALL mice model (SNP) Refer to individual Series

ORGANISM(S): Homo sapiens  

SUBMITTER: Xabier Agirre  

PROVIDER: E-GEOD-26807 | ArrayExpress | 2012-04-17

SECONDARY ACCESSION(S): GSE26807PRJNA135889

REPOSITORIES: GEO, ArrayExpress

altmetric image

Publications


Histone deacetylases (HDACs) have been identified as therapeutic targets due to their regulatory function in chromatin structure and organization. Here, we analyzed the therapeutic effect of LBH589, a class I-II HDAC inhibitor, in acute lymphoblastic leukemia (ALL). In vitro, LBH589 induced dose-dependent antiproliferative and apoptotic effects, which were associated with increased H3 and H4 histone acetylation. Intravenous administration of LBH589 in immunodeficient BALB/c-RAG2(-/-)γc(-/-) mice  ...[more]

Similar Datasets

| PRJNA135889 | ENA
| PRJNA142119 | ENA
| PRJNA142117 | ENA
| PRJNA142115 | ENA
| PRJNA142113 | ENA
2012-04-18 | GSE26790 | GEO
2012-04-17 | E-GEOD-26791 | ArrayExpress
2012-04-17 | E-GEOD-26789 | ArrayExpress
2012-04-17 | E-GEOD-26792 | ArrayExpress
2012-04-17 | E-GEOD-26790 | ArrayExpress